ABCD1 Gene Mutations: Mechanisms and Management of Adrenomyeloneuropathy
Abstract
Pathogenic variants in the ABCD1 gene on the X chromosome may result in widely heterogenous phenotypes, including adrenomyeloneuropathy (AMN). Affected males typically present in their third or fourth decade of life with progressive lower limb weakness and spasticity, and may develop signs and symptoms of adrenal insufficiency and/or cerebral demyelination. Heterozygous females may be asymptomatic, but may develop a later-onset and more slowly progressive spastic paraparesis. In this review, we describe the clinical presentation of AMN, as well as its diagnosis and management. The role of rehabilitative therapies and options for management of spasticity are highlighted.
Read the paper
Related studies
- Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction
- Treatment of Benign Prostatic Hyperplasia by Natural Drugs
- Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives
- Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives-
- Underactive Bladder and Detrusor Underactivity: New Advances and Prospectives
- Drugs Currently Undergoing Preclinical or Clinical Trials for the Treatment of Overactive Bladder: A Review
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.